Biomarker Accuracy for Dementia Classification: A Systematic Review

Several imaging and cerebrospinal fluid biomarkers have moderate to high sensitivities and specificities for dementia classification.

Biomarkers may help in determining the underlying cause of dementia in a given patient. In this systematic review, investigators analyzed data from 15 neuroimaging and 9 cerebrospinal fluid (CSF) biomarker studies to determine their accuracy in distinguishing neuropathologically defined Alzheimer disease (AD) from non-AD dementia. Criteria for neuropathologically defined AD were heterogeneous across studies. Study size ranged from 27 to 217 participants, who were predominantly white, about 50% male, and had a mean age of dementia symptom onset of about 65 years.

Key Findings from Neuroimaging Studies

Amyloid positron emission tomography (PET) imaging had high sensitivity (0.91) and specificity (0.92) for distinguishing AD from non-AD. Cut poi…

Reviewing Author

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Biomarker Accuracy for Dementia Classification: A Systematic Review

Topics

Key Findings from Neuroimaging Studies

Reviewing Author